Events

Our annual conference took place on Wednesday the 22nd March – Thursday 23rd March at Jesus College, Cambridge. We were excited to welcome everyone back face-to-face and had some brilliant keynote talks from Professors Claire Foster, David French and Jo Waller. Attendees were able to talk part in either a communication workshop or a round table discussion about collecting longitudinal data. Programme details can be found here: https://www.delegate-reg.co.uk/bpos2023/programme 

Read more about our other past events here:

Our annual conference resumed virtually on Thursday the 28th – Friday the 29th April 2022. The theme for this conference was Equality, Diversity and Inclusion in psychosocial oncology. We had the following keynote presentations:

• Sean Ralph, Consultant Therapeutic Radiographer in prostate cancer, Leeds Teaching Hospitals NHS Trust 
• Prof Afaf Girgis, Honorary Professor, Psycho-oncology Research Group, Ingham Institute for Applied Medical Research, University of New South Wales, Sydney
• Zahida Ramzan-Asghar, Senior Lawyer, Government Legal Department

We organised a joint NCRI/BPOS webinar: Living with and beyond cancer research post-pandemic: What have we learnt? taking place on Thursday 9th September 10.30am-12pm.

The session included the following speakers:

• Professor Deborah Lupton – University of New South Wales, Australia: Insights from ‘Doing Fieldwork in a pandemic’ (focus on qualitative methods)
• Professor Eila Watson – Oxford Brookes University, UK: Experiences of delivering the SWEET NIHR funded research programme during the covid-19 pandemic
• Ms Michelle Collinson & Dr Alexandra Gilbert  – University of Leeds, UK: Impact of the covid-19 pandemic on conducting and delivering clinical trials

We have also worked with the British Psychological Society (BPS) Faculty for Oncology and Palliative Care to host a joint event on the current and future impact of the covid-19 pandemic on psycho-oncology.

Our student branch organised an event, ‘Perspectives on conducting psychosocial oncology research during the COVID-19 pandemic’.